Canadian Journal of Infectious Diseases and Medical Microbiology

Canadian Journal of Infectious Diseases and Medical Microbiology / 1994 / Article

Open Access

Volume 5 |Article ID 498379 |

Charles A Dinarello, "Anti-Interleukin-1 Strategies in the Treatment of the Septic Shock Syndrome", Canadian Journal of Infectious Diseases and Medical Microbiology, vol. 5, Article ID 498379, 8 pages, 1994.

Anti-Interleukin-1 Strategies in the Treatment of the Septic Shock Syndrome


The septic shock syndrome has recently been termed the systemic inflammatory response syndrome (SIRS). It is an acute illness characterized by generalized activation of the endothelium. The most severe and most common form of the syndrome is found in patients wilh shock due to Gram-negative sepsis. In this overview. both animal and limited human data are considered for the contribution of the cytokine interleukin-1 (IL-1) to this syndrome. Cytokines are small molecular weight, endogenously produced proteins with multiple biological effects. Laboratory investigations suggest that IL-1 plays a critical role in SIRS by promoting the biochemical and clinical characteristics of SIRS. The biochemical changes induced by IL-1 are similar to those of tumour necrosis factor (TNF) and include increased synthesis of nitric oxide, prostaglandins, platelet activating factor and endothelial cell adhesion molecules. Togelher, IL-1 and TNF appear to act in a synergistic fashion in a variety of disease models. particularly SRIS. Specific blockade of IL-1 using soluble IL-1 receptors or IL-1 receptor antagonist suggests that blocking this cytokine may be useful in treating human SIRS.

Copyright © 1994 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.